JP2020515530A5 - - Google Patents

Info

Publication number

JP2020515530A5

JP2020515530A5 JP2019546249A JP2019546249A JP2020515530A5 JP 2020515530 A5 JP2020515530 A5 JP 2020515530A5 JP 2019546249 A JP2019546249 A JP 2019546249A JP 2019546249 A JP2019546249 A JP 2019546249A JP 2020515530 A5 JP2020515530 A5 JP 2020515530A5

Authority

JP

Japan

Prior art keywords

glatiramer

baseline

depot

depot preparation

weeks

Prior art date

2018-03-25

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims 19
• 239000003405 delayed action preparation Substances 0.000 claims 18
• 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 17
• 238000013268 sustained release Methods 0.000 claims 17
• 239000012730 sustained-release form Substances 0.000 claims 17
• 108010072051 Glatiramer Acetate Proteins 0.000 claims 13
• 229940042385 glatiramer Drugs 0.000 claims 11
• 238000009472 formulation Methods 0.000 claims 10
• 239000000203 mixture Substances 0.000 claims 10
• 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 9
• 150000003839 salts Chemical class 0.000 claims 8
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 8
• 230000003902 lesion Effects 0.000 claims 7
• 210000004556 brain Anatomy 0.000 claims 6
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 5
• 229910052688 Gadolinium Inorganic materials 0.000 claims 3
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 3
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical group CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
• 229920001577 copolymer Polymers 0.000 claims 2
• 229960003776 glatiramer acetate Drugs 0.000 claims 2
• 238000000034 method Methods 0.000 claims 2
• 239000002953 phosphate buffered saline Substances 0.000 claims 2
• 208000024891 symptom Diseases 0.000 claims 2
• 206010069632 Bladder dysfunction Diseases 0.000 claims 1
• 208000028698 Cognitive impairment Diseases 0.000 claims 1
• 206010061818 Disease progression Diseases 0.000 claims 1
• 208000026139 Memory disease Diseases 0.000 claims 1
• 206010047571 Visual impairment Diseases 0.000 claims 1
• 230000002490 cerebral effect Effects 0.000 claims 1
• 208000010877 cognitive disease Diseases 0.000 claims 1
• 230000001054 cortical effect Effects 0.000 claims 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
• 230000005750 disease progression Effects 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 208000035475 disorder Diseases 0.000 claims 1
• 230000004064 dysfunction Effects 0.000 claims 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
• 230000001771 impaired effect Effects 0.000 claims 1
• 230000000968 intestinal effect Effects 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 230000002459 sustained effect Effects 0.000 claims 1
• 230000009747 swallowing Effects 0.000 claims 1
• 208000029257 vision disease Diseases 0.000 claims 1
• 230000004393 visual impairment Effects 0.000 claims 1